MX2012000441A - Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. - Google Patents

Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer.

Info

Publication number
MX2012000441A
MX2012000441A MX2012000441A MX2012000441A MX2012000441A MX 2012000441 A MX2012000441 A MX 2012000441A MX 2012000441 A MX2012000441 A MX 2012000441A MX 2012000441 A MX2012000441 A MX 2012000441A MX 2012000441 A MX2012000441 A MX 2012000441A
Authority
MX
Mexico
Prior art keywords
sup
bond
cancer
treatment
thiazolidin
Prior art date
Application number
MX2012000441A
Other languages
English (en)
Other versions
MX337516B (es
Inventor
Jacob Westman
Allan Hallett
Jan Vagberg
Original Assignee
Baltic Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baltic Bio Ab filed Critical Baltic Bio Ab
Publication of MX2012000441A publication Critical patent/MX2012000441A/es
Publication of MX337516B publication Critical patent/MX337516B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

De acuerdo con la invención se provee un compuesto de la fórmula (I) en donde: A representa C(N-W-D) o S; B representa S o C(-NH W-D); cuando A representa C(=N-W-D) y B representa S, entonces el enlace entre B y el átomo de NH es un enlace sencillo; o cuando A representa S y B representa C(-NH-W-D), entonces el enlace entre B y el átomo de NH es un enlace doble; X representa -Q-[CRxRY]n-; W representa [CRXRY]m o -C(O)- [CRXR]p-, Q representa un enlace, -N(Ra), -S-, u -O-; A1 a A5 representan, respectivamente, C(R1), C(R2), C(R3), C(R4) y C(R5), o alternativamente hasta dos de A1 a A5 pueden representar independientemente N; D representa fenilo, piridilo o pirimidinilo, sustituido opcionalmente con uno o más grupos R6 dichos compuestos son útiles en el tratamiento del cáncer.
MX2012000441A 2009-07-08 2010-07-08 Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer. MX337516B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21373509P 2009-07-08 2009-07-08
PCT/GB2010/001315 WO2011004162A2 (en) 2009-07-08 2010-07-08 Compounds useful as medicaments

Publications (2)

Publication Number Publication Date
MX2012000441A true MX2012000441A (es) 2012-04-19
MX337516B MX337516B (es) 2016-03-09

Family

ID=43086401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000441A MX337516B (es) 2009-07-08 2010-07-08 Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer.

Country Status (24)

Country Link
US (2) US9162994B2 (es)
EP (1) EP2451794B1 (es)
JP (1) JP5982281B2 (es)
KR (1) KR101765957B1 (es)
CN (1) CN102596923B (es)
AU (1) AU2010270030B2 (es)
BR (1) BR112012000370B1 (es)
CA (1) CA2767291C (es)
DK (1) DK2451794T3 (es)
EA (1) EA026674B1 (es)
ES (1) ES2567753T3 (es)
HR (1) HRP20160353T1 (es)
HU (1) HUE027263T2 (es)
IL (1) IL216723A (es)
ME (1) ME02443B (es)
MX (1) MX337516B (es)
NZ (1) NZ597075A (es)
PL (1) PL2451794T3 (es)
RS (1) RS54718B1 (es)
SG (1) SG177558A1 (es)
SI (1) SI2451794T1 (es)
SM (1) SMT201600225B (es)
WO (1) WO2011004162A2 (es)
ZA (1) ZA201108901B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931145B1 (ko) * 2008-07-04 2009-12-10 현대자동차주식회사 조정식 킥 다운 스위치의 조작기구
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
UA123810C2 (uk) 2017-01-23 2021-06-02 Цадент Терапеутікс, Інк. Модулятори калієвих каналів
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
US20220023269A1 (en) * 2018-11-05 2022-01-27 Balticgruppen Bio Ab Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects
CN109879808B (zh) * 2019-03-05 2020-10-16 北京工业大学 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途
GB201910093D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201910092D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
WO2025017193A1 (en) 2023-07-20 2025-01-23 Betagenon Ab Methods of treating cardiomyopathy induced by metabolic inflexibility
WO2025017194A1 (en) 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler
WO2025027205A1 (en) 2023-08-03 2025-02-06 Betagenon Ab Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
KR20080034436A (ko) 2005-07-21 2008-04-21 베타게논 에이비 암 치료에 사용되는 티아졸 유도체 및 유사체
WO2008090356A1 (en) 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity

Also Published As

Publication number Publication date
HRP20160353T1 (hr) 2016-05-06
JP5982281B2 (ja) 2016-08-31
EA201200102A1 (ru) 2012-08-30
DK2451794T3 (en) 2016-03-14
ES2567753T3 (es) 2016-04-26
KR20120054568A (ko) 2012-05-30
ME02443B (me) 2016-09-20
WO2011004162A3 (en) 2011-03-03
SG177558A1 (en) 2012-02-28
EP2451794B1 (en) 2016-01-27
NZ597075A (en) 2013-03-28
WO2011004162A2 (en) 2011-01-13
US9675596B2 (en) 2017-06-13
CN102596923A (zh) 2012-07-18
IL216723A0 (en) 2012-03-01
MX337516B (es) 2016-03-09
ZA201108901B (en) 2017-08-30
KR101765957B1 (ko) 2017-08-07
CA2767291C (en) 2020-01-28
US20120183537A1 (en) 2012-07-19
BR112012000370A2 (pt) 2016-11-22
EA026674B1 (ru) 2017-05-31
RS54718B1 (sr) 2016-08-31
IL216723A (en) 2017-09-28
AU2010270030A1 (en) 2012-01-12
JP2012532854A (ja) 2012-12-20
HUE027263T2 (en) 2016-10-28
AU2010270030B2 (en) 2015-12-24
EP2451794A2 (en) 2012-05-16
SI2451794T1 (sl) 2016-05-31
US20160128993A1 (en) 2016-05-12
CN102596923B (zh) 2015-04-29
HK1170485A1 (zh) 2013-03-01
SMT201600225B (it) 2016-08-31
US9162994B2 (en) 2015-10-20
PL2451794T3 (pl) 2016-07-29
CA2767291A1 (en) 2011-01-13
BR112012000370B1 (pt) 2019-04-16

Similar Documents

Publication Publication Date Title
MX2012000441A (es) Derivados de 1,2,4-tiazolidin-3-ona y uso en el tratamiento del cancer.
MY151556A (en) Organic compounds
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
MY168201A (en) Agricultural And Horticultural Fungicidal Composition
MX2010005109A (es) Compuestos herbicidas.
IN2012DN00869A (es)
MY161890A (en) Pyrazolylaminopyridines as inhibitors of fak
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MY177250A (en) Novel nicotinamide derivative or salt thereof
UA94833C2 (en) Substituted bicyclolactams
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
WO2008108380A3 (en) Pyrrole compounds
MX2009007482A (es) Agentes antiparasitarios.
TW200740752A (en) 4-Biarylyl-1-phenylazetidin-2-ones
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
PA8792101A1 (es) Nuevo procedimiento de sintesis del ( 7-metoxi-1- naftil) aceto
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
MY149070A (en) 1h-quinazoline-2,4-diones
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
TR201818771T4 (tr) Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler

Legal Events

Date Code Title Description
FG Grant or registration